Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
This study is recruiting at 19 US sites in 18 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Locoregional Recurrence
- Hormone Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Oana Danciu
- Last updated on ClinicalTrials.gov
- July 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Arizona · 1
- University of Arizona · Phoenix, AZ
District of Columbia · 1
- Georgetown University · Washington D.C., DC
Illinois · 1
- University of Illinois Cancer Center · Chicago, IL
Indiana · 1
- Parkview Research Center · Fort Wayne, IN
Iowa · 1
- University of Iowa Hospitals and Clinics · Iowa City, IA
Massachusetts · 1
- Tufts Medical Center · Boston, MA
Michigan · 1
- University of Michigan Health System · Ann Arbor, MI
Nebraska · 1
- University of Nebraska Medical Center · Omaha, NE
New Jersey · 1
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
New Mexico · 1
- University of New Mexico Comprehensive Cancer Center · Albuquerque, NM
New York · 1
- New York University Clinical Cancer Center · New York, NY
Ohio · 1
- Ohio State University Comprehensive Cancer Center · Columbus, OH
Oregon · 1
- Providence Portland Medical Center · Portland, OR
Pennsylvania · 1
- Penn State Cancer Institute · Hershey, PA
South Carolina · 1
- Medical University of South Carolina · Charleston, SC
Virginia · 2
- University of Virginia Health System · Charlottesville, VA
- Virginia Commonwealth University · Richmond, VA
Wisconsin · 1
- University of Wisconsin · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.